Literature DB >> 34318378

Content validation of a self-report daily diary in patients with sickle cell disease.

Michelle K White1, Cory Saucier2, Miranda Bailey3, Denise D'Alessio3, April Foster2, Danielle St Pierre4, Kimberly Raymond2.   

Abstract

BACKGROUND: Sickle Cell Disease (SCD) is a genetic progressive vascular disease that impacts patients overall health and quality of life. Sickle-cell pain crises (SCPCs) are a hallmark clinical presentation of SCD and have been associated with increased morbidity and mortality. The Sickle Cell Pain Diary- Self Report (SCPD-S) was developed as a daily patient-reported outcome (PRO) measure primarily intended to capture the frequency and severity of SCD-related pain during and outside of a SCPC. The SCPD-S also examines the impact of the pain associated with an SCPC on other health-related quality of life concepts. The objective of this study was to investigate the content validity of the SCPD-S.
METHODS: The content validation testing included 18 in-depth hybrid concept elicitation and cognitive debriefing interviews conducted with SCD patients in the US aged 12 years and older. Interviewers used a semi-structured interview guide and a think-aloud approach for the cognitive debriefing portion. All interviews were recorded, transcribed, coded and analyzed.
RESULTS: Eighteen interviews across two rounds were conducted. Round 1 hybrid interviews (n = 12) resulted in the expansion of the SCPD-S from 13 to 19 items. Items on the impact of an SCPC on social and recreational activities, sleep, and emotional well-being were added. Five items were significantly revised, as were three response choice sets. Round 2 hybrid interviews (n = 6) confirmed the comprehensiveness of the revised diary, understandability of the wording, and appropriateness of the recall period and response sets. Saturation analyses specific to concept elicitation revealed that no additional interviews were needed.
CONCLUSIONS: This study provided evidence to support the content validity of the SCPD-S, a self-report daily diary. Data gathered during patient interviews indicated that the SCPD-S is a fit for purpose measure of SCD and SCPC-related pain frequency and severity and the impact of this pain on other health-related quality of life concepts including fatigue and emotional health. The numerous changes to the SCPD-S as a result of the study findings highlight the importance of the content validation process when developing a PRO measure.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34318378     DOI: 10.1186/s41687-021-00337-7

Source DB:  PubMed          Journal:  J Patient Rep Outcomes        ISSN: 2509-8020


  15 in total

1.  The number of people with sickle-cell disease in the United States: national and state estimates.

Authors:  David C Brousseau; Julie A Panepinto; Mark Nimmer; Raymond G Hoffmann
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

2.  Race matters: perceptions of race and racism in a sickle cell center.

Authors:  Stephen C Nelson; Heather W Hackman
Journal:  Pediatr Blood Cancer       Date:  2012-09-28       Impact factor: 3.167

3.  Health-related stigma in young adults with sickle cell disease.

Authors:  Coretta M Jenerette; Cheryl Brewer
Journal:  J Natl Med Assoc       Date:  2010-11       Impact factor: 1.798

4.  Pain, quality of life, and coping in sickle cell disease.

Authors:  P Fuggle; P A Shand; L J Gill; S C Davies
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 5.  Management of sickle cell disease from childhood through adulthood.

Authors:  Julie Kanter; Rebecca Kruse-Jarres
Journal:  Blood Rev       Date:  2013-09-19       Impact factor: 8.250

Review 6.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

7.  Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.

Authors:  Kenneth I Ataga; Abdullah Kutlar; Julie Kanter; Darla Liles; Rodolfo Cancado; João Friedrisch; Troy H Guthrie; Jennifer Knight-Madden; Ofelia A Alvarez; Victor R Gordeuk; Sandra Gualandro; Marina P Colella; Wally R Smith; Scott A Rollins; Jonathan W Stocker; Russell P Rother
Journal:  N Engl J Med       Date:  2016-12-03       Impact factor: 91.245

8.  Prevalence of stroke in children admitted with sickle cell anaemia to Mulago Hospital.

Authors:  Deogratias Munube; Elly Katabira; Grace Ndeezi; Moses Joloba; Samden Lhatoo; Martha Sajatovic; James K Tumwine
Journal:  BMC Neurol       Date:  2016-09-17       Impact factor: 2.474

9.  Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.

Authors:  Poulami Maitra; Melissa Caughey; Laura Robinson; Payal C Desai; Susan Jones; Mehdi Nouraie; Mark T Gladwin; Alan Hinderliter; Jianwen Cai; Kenneth I Ataga
Journal:  Haematologica       Date:  2017-01-19       Impact factor: 9.941

10.  Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.

Authors:  Sherif M Badawy; Alexis A Thompson; Jin-Shei Lai; Frank J Penedo; Karen Rychlik; Robert I Liem
Journal:  Health Qual Life Outcomes       Date:  2017-07-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.